OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief executive officer Gary Jacob has purchased 10,000 of the company’s shares at US$1.04 per share.
Additionally, Panetta Partners, in which executive chairman Gabriele Cerrone holds a beneficial interest, purchased 20,000 shares at the same price.
This brings Cerrone’s stake in the company to approximately 9.87 billion shares or about 29% of issued share capital.
OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing novel treatments for neuropathic corneal pain (NCP) and dry eye disease (DED).